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Objective: Fentanyl-induced cough is usually mild and transitory, but it can be undesirable in patients with
increased intracranial pressure, open wounds of the eye, dissecting aortic aneurism, pneumothorax, and reactive
airway disease. The aim of this study is to evaluate the efficacy of lidocaine in suppressing fentanyl-induced cough
in children during induction in general anesthesia.
Methods: One hundred and eighty-six children of both sexes, aged between 4–10 years, ASA physical status I and
II, and scheduled for elective surgery, were recruited for the study. Patients with a history of bronchial asthma,
obstructive pulmonary disease, or infections of the respiratory tract were excluded. Patients were randomly
allocated to three equal groups (n = 62) to receive 1.0 mg/kg lidocaine (Group I), 0.5 mg/kg lidocaine (Group II),
or placebo (equal volume of 0.9% saline; Group III). Each was administered over 5 s one minute before intravenous
(IV) administration of fentanyl 2−3 μg/kg during induction in general anesthesia. The severity of coughing was
graded by counting the number of episodes of cough: mild (1−2), moderate (3−4) or severe (5 or more).
Results: Demographic information was comparable between groups. The most frequent coughing was observed in
the placebo group (Group III; 43.5%), of whom 4.8% (three patients) were graded with severe cough. In Group II,
22.6% patients had cough, of which 1.6% (one patient) was graded as severe. In Group I, 16.1% patients had cough,
none of whom were graded as severe.
Conclusion: Our results demonstrate that IV lidocaine can markedly suppress fentanyl-induced cough in children,
even in doses as low as 0.5 mg/kg.
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Opioids are known for their antitussive effect, but often,
intravenous administration of fentanyl during the induc-
tion of anesthesia paradoxically induces cough [1-5], al-
though the exact mechanisms of fentanyl-induced cough
still remain unclear. Fentanyl is commonly used as a
preinduction adjunct in children. Fentanyl-induced cough
is quite common and benign, but sometimes it may be ex-
plosive and can be associated with an increase in intraocu-
lar, intracranial, and intra-abdominal pressures, which may
require immediate treatment [3,4,6]. Intravenous adminis-
tration of lidocaine suppresses the cough reflex during
endotracheal intubation, extubation, bronchography, bron-
choscopy, and laryngoscopy [7-9]. Oshima et al. showed* Correspondence: agretag@yahoo.com
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distribution, and reproduction in any mediumthat one of the significant independent risk factors for the
development of fentanyl- induced cough is young age [10].
However, we have not found any study that has specifically
evaluated fentanyl-induced cough in pediatric patients ex-
cept for two case reports [3,6]. Thus, this study evaluated
the effect of IV lidocaine in suppressing fentanyl–induced
cough in pediatric patients during induction of general
anesthesia.Methods
After ethics committee approval and parent/guardian
consent, 186 children of either sex, aged between 4 and
10 years, ASA physical status I and II, and scheduled for
elective surgery were recruited for the study. The exclu-
sion criteria were body weight exceeding 20% of the
ideal body weight, a history of bronchial asthma and
chronic obstructive pulmonary disease, respiratory tractntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.





Total Mild Moderate Severe
Group I
N 52 10 8 2 0
% 83.9 16.1 12.9 3.2 0.0
Group II
N 48 14 10 3 1
% 77.4 22.6 16.1 4.8 1.6
Group III
N 35 27 19 5 3
% 56.5 43.5 30.6 8.1 4.8
Incidence of cough Gr. I vs. Gr. III, P = 0.002; Gr. II vs. Gr. III, P = 0.022.
Cough severity P = 0.441.
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logical or emotional disorders and development delay,
and with malformation of the tongue and oropharynx.
All patients received an oral administration of 0.3 mg/kg
of injectable midazolam mixed with a double volume
apple juice 30 minutes before separation from parents or
IV (1 mg) and atropine (0.02 mg/kg) when IV access was
established before the induction of anesthesia. Upon
arrival in the operating room (OR), intravenous access
was established, standard monitoring including electro-
cardiography (5 leads), noninvasive blood pressure, pulse
oximetry and capnography were connected, and the
baseline vital parameters were noted. All patients were
preoxygenated with 100% O2 for 5 minutes. Patients
were randomly allocated using the sealed envelope tech-
nique in three groups of 62 each to receive: 1.0 mg/kg
lidocaine (Gr I), 0.5 mg/kg lidocaine (Gr II) or placebo -
equal volume of 0.9% saline (Gr III), over 5 s 1 min be-
fore the IV administration of 2–3 μg/kg fentanyl during
induction of general anesthesia. A blinded observer, who
was unaware of the type of medication given to the pa-
tients, recorded the number of coughing episodes. Sever-
ity of coughing was graded based on the number of
episodes of cough (mild, 1–2; moderate, 3–4; and severe,
5 or >5).
Data processing was done with the statistical package R.
The statistical parameters index structure, arithmetic
mean, standard deviation, minimum and maximum values
were calculated. One-Way ANOVA with post-hoc testing
was used to test parametric data, whereas χ2-test and
Kruskal Wallis test with post-hoc testing were used for
nonparametric data. A P value of <0.05 was considered
statistically significant.
Results
There was no statistically significant difference between
the three groups with regard to age, weight, sex, and
ASA class (P > 0.05). Table 1. Demographic patient char-








Gender F 33 (53.2%) 32 (51.6%) 33 (53.2%)
P = 0.982
N (%) M 29 (46.8%) 30 (48.4%) 29 (46.8%)
Age (year) Mean ± SD 6.8 ± 2.0 7.0 ± 2.2 7.1 ± 2.2
P = 0.692
Rank 4-10 4-10 4-10
Weight (kg) Mean ± SD 24.5 ± 4.6 25.6 ± 5.0 25.7 ± 4.7
P = 0.261
Rank 16 - 35 16 - 36 17 - 36
ASA I 52 (83.9%) 49 (79.0%) 53 (85.5%)
P = 0.716
N (%) II 10 (16.1%) 13 (21.0%) 9 (14.5%)coughing and its severity in groups. The highest fre-
quency of coughing was found in the placebo group (GR
III), with 43.5% having cough, of which 4.8% (3 patients)
had severe cough. In Group II, 22.6% had cough of
which 1.6% (1 patient) had severe cough, whereas in
Group I 16.1% had cough and none had severe cough.
With the Chi-square test, we have gained significant dif-
ference in the incidence of cough between the first and
the third groups (P <0.01), and between the second and
the third groups (P <0.05). According to the severity of
coughing between groups we have not gained the statis-
tically significant difference (P > 0.05).
Discussion
In our study, we have shown that administration of 2–
3 μg/kg fentanyl through a peripheral venous line in-
duced reflex cough in 43.5% of patients in the placebo
group, 22.6% in the 1-mg/kg lidocaine group, and 16.1%
in the 0.5-mg/kg lidocaine group. Phua et al. reported
that 1.5 μg/kg fentanyl given through a peripheral vein
elicited cough in 28% of the patients and a similar inci-
dence of cough was observed by Agarwal et al. following
2 μg/kg IV fentanyl through the same route over a
period of 5 seconds [2,4]. Bohrer et al. observed a 45%
incidence of cough when 7 μg/kg fentanyl was adminis-
tered through a central venous catheter over 1 second,
whereas a 46% incidence was reported by Lui et al. with
5 μg/kg fentanyl administered through a peripheral vein
over 5 seconds [1,11]. In all the above studies, benign
cough has been reported, which is consistent with our
results. However, Tweed and Dakin reported a case of
explosive coughing in a 7-yr-old boy with Trisomy-21
syndrome, after peripheral injection of IV fentanyl
(2 μg/kg) that produced periorbital petechiae and was
only relieved after induction of anesthesia [3]. Also,
Ambesh et al. reported a known case of arteriovenous
malformation of tongue and oropharynx of a 12-year-old
patient with severe spasmodic cough after receiving IV
fentanyl (50 μg), which led to massive engorgement of the
tongue and hypopharynx that caused acute airway
obstruction and severe hypoxia [6]. In our study, we
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malformation in the oral cavity or pharynx. However, it was
interesting that one patient in Group II and two of three
patients in Group III, who were classified as having severe
cough, presented with hypertrophied tonsils without local
inflammation. There are various hypotheses that try to ex-
plain the mechanism of fentanyl-induced cough. According
to some studies, fentanyl may inhibit central sympathetic
outflow causing vagal predominance, which could trigger
cough and reflex bronchoconstriction [4,9,12].
However, the involvement of a vagal-dependent path-
way was not supported by some studies because atropine
failed to suppress cough [2,9,10]. In our study, we have
used atropine before fentanyl in all groups, so we were
not able to evaluate the effect of atropine in suppression
of fentanyl-induced cough. Additionally, a possible
mechanism of fentanyl-induced cough is a pulmonary
chemoreflex mediated by either irritant receptors or by
vagal C fibre receptors that are close to pulmonary ves-
sels [1,13]. Effective suppression of the cough response
from 43% to 3% after terbutaline and salbutamol inhal-
ation supports the concept of bronchoconstriction [11].
Also, suppression of cough with betamethasone inhalation
supports the trigger stimulus and bronchial hyperirritabil-
ity theory [3,4,11]. According to Kamei et al. pretreatment
with fentanyl significantly increased the number of citric
acid-induced coughs in mice, and this effect was antago-
nized by pretreatment with moguisteine, a rapidly adapting
receptor antagonist, which suggest that fentanyl activates
mainly rapidly adapting receptors, but not C-fibers, to en-
hance citric acid-induced cough [14]. The release of hista-
mine, leukotrienes, interleukins, and other inflammatory
mediators from mast cells in the lungs and the possible
stimulation of irritant receptors in the tracheobronchial
wall are other possible mechanisms of fentanyl-induced
cough [4,15,16].
Has been reported that fentanyl did not induce the re-
lease of histamine in plasma [17], even during incuba-
tion of human skin mast cells with fentanyl [18]. But,
Kamei et al. also observed that fentanyl markedly in-
creased the histamine levels in bronchoalveolar lavage
fluid (BALF), and this suggest that histamine may en-
hance cough receptor sensitivity through the activation
of histamine H1 receptors in the airways, and it is pos-
sible that mast cell heterogenity may play a role in the
different effects of fentanyl on histamine release [14].
There are so many clinical studies showed that IV
lidocaine before fentanyl administration during induc-
tion in general anesthesia, suppress fentanyl-induced
cough significantly [5,7,8,19,20]. The precise mechanisms
by which intravenous lidocaine prevent fentanyl-induced
cough are not clear. There are 4 groups of airway sensory
receptors innervated by vagus nerve: slowly adapting re-
ceptors (SARs), rapidly adapting receptors (RARs), high-threshold Aδ-receptors (HTARs)and C-fiber receptors
(CFRs) [21-24], that participate in various reflexes such as
coughing and sneezing, and in respiratory and cardiovas-
cular performance [21,22]. Mechanosensors (SARs and
RARs) are suppressed whereas the chemosensors (CFRs
and HTARs) are stimulated by lidocaine [25].
It has been proposed that depression of brain stem
functions by lidocaine may be responsible for cough sup-
pression or lidocaine may act by anesthetizing peripheral
cough receptors in the trachea and hypopharynx [26].
Although the bronchodilating effect of lidocaine has not
been confirmed, the intravenous administration of lido-
caine suppress mechanically and chemically induced air-
way reflexes, including the cough reflex [6,8,15,26,27].
The airways are innervated by C-fibers, which express
voltage-gated Na+ channels with sensitivity or resistance
to tetrodotoxin (TTX). Kamei et al. indicate that sodium
channels, mainly TTX-resistant sodium channels, may
play an important role in the enhancement of C-fiber-
mediated cough pathways [28]. However, the role of TTX-
resistant sodium channels in the cough reflex is not well
understood.
Lidocaine is showed to be effective antitussive agent
who blocks sensory neuron voltage-gated sodium chan-
nels and suppresses action potential generation and
propagation of neurons, the mechanism of action
likely involves a reduction in action potential forma-
tion evoked by a variety of stimuli in several airway
afferent nerve subtypes [29].
Although precise mechanisms of how fentanyl induces
cough and lidocaine prevents fentanyl- induced cough
are not yet clear, our results demonstrate that IV lido-
caine can prevent markedly, fentanyl-induced cough in
pediatric patients during induction of general anesthesia
even in doses of 0.5 mg/kg (77.4%).
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